Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.1% – What’s Next?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s stock price fell 5.1% during trading on Tuesday . The stock traded as low as $3.97 and last traded at $3.9950. Approximately 897,500 shares were traded during trading, a decline of 74% from the average session volume of 3,444,271 shares. The stock had previously closed at $4.21.

Wall Street Analyst Weigh In

A number of analysts have recently commented on IRWD shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Finally, Zacks Research upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Price Performance

The firm has a 50 day simple moving average of $3.85 and a 200-day simple moving average of $3.97. The stock has a market capitalization of $652.24 million, a price-to-earnings ratio of 6.67 and a beta of 0.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The business had revenue of $106.51 million during the quarter, compared to analyst estimates of $92.11 million. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the transaction, the insider directly owned 313,680 shares in the company, valued at $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director owned 250,749 shares in the company, valued at $935,293.77. This represents a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 9.30% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Range Financial Group LLC bought a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at approximately $1,436,000. Hillsdale Investment Management Inc. purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at approximately $3,897,000. GSA Capital Partners LLP grew its holdings in Ironwood Pharmaceuticals by 84.7% during the 4th quarter. GSA Capital Partners LLP now owns 571,613 shares of the biotechnology company’s stock valued at $1,926,000 after buying an additional 262,084 shares in the last quarter. WINTON GROUP Ltd purchased a new position in Ironwood Pharmaceuticals during the fourth quarter worth $554,000. Finally, Persistent Asset Partners Ltd bought a new position in Ironwood Pharmaceuticals in the 4th quarter valued at $613,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.